[Asp371]-Tyrosinase (369-377) (human) (trifluoroacetate salt)
(Synonyms: Asp370-Tyrosinase (368-376),Tyr-Met-Asp-Gly-Thr-Met-Ser-Gln-Val) 目录号 : GC91836[Asp371]-Tyrosinase (369-377) is a naturally occurring tyrosinase antigen peptide.
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
[Asp371]-Tyrosinase (369-377) is a naturally occurring tyrosinase antigen peptide.[1] It is formed via post-translational modification of Asn371.[2] [Asp371]-Tyrosinase (369-377) binds to MHC class I subtype HLA-A*0201-positive T2 cells (IC50 = 1.2 µg/ml) and induces lysis of HLA-A2.1-positive T2 cells incubated with cytotoxic T lymphocytes in a concentration-dependent manner.3,1 Immunization with [Asp371]-tyrosinase (369-377)-pulsed, CD40L-activated autologous dendritic cells delays tumor growth in an AAD-expressing B16-F1 melanoma model using transgenic mice expressing HLA-A*0201 linked to the CD8-binding domain of H-2Dd (AAD).[4]
References:
[1].Skipper, J.C.H., R.C., Gulden, P.H., Brichard, V., et al.An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteinsJ. Exp. Med.83(2)527-534(1996).
[2].Mosse, C.A., Meadows, L., Luckey, C.J., et al.The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosolJ. Exp. Med.87(1)37-48(1998).
[3].van Elsas, A., van der Burg, S.H., van der Minne, C.E., et al.Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigenEur. J. Immunol.26(8)1683-1689(1996).
[4].Mullis, D.W., Bullock, T.N.J., Colella, T.A., et al.Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic miceJ. Immunol.67(9)4853-4860(2001).
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.9697 mL | 4.8487 mL | 9.6974 mL |
5 mM | 0.1939 mL | 0.9697 mL | 1.9395 mL |
10 mM | 0.097 mL | 0.4849 mL | 0.9697 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。